104 related articles for article (PubMed ID: 441510)
1. Amino acid conferred protection against melphalan: comparison of amino acids which reduce melphalan toxicity to murine bone marrow precursor cells (CFU-C) and murine L1210 leukemia cells.
Vistica DT; Rabon A; Rabinovitz M
Res Commun Chem Pathol Pharmacol; 1979 Jan; 23(1):171-83. PubMed ID: 441510
[TBL] [Abstract][Full Text] [Related]
2. Amino acid-conferred resistance to melphalan. I. Structure-activity relationship in cultured murine L1210 leukemia cells.
Vistica DT; Toal JN; Rabinovitz M
Cancer Treat Rep; 1976 Sep; 60(9):1363-7. PubMed ID: 1016969
[TBL] [Abstract][Full Text] [Related]
3. Amino acid conferred protection against melphalan: interference with leucine protection of melphalan cytotoxicity by the basic amino acids in cultured murine L1210 leukemia cells.
Vistica DT; Toal JN; Rabinovitz M
Mol Pharmacol; 1978 Nov; 14(6):1136-42. PubMed ID: 732811
[No Abstract] [Full Text] [Related]
4. Antitumor activity and bone marrow toxicity of aminoglucose mustard anticancer agents in mice.
Cantrell JE; Green D; Schein PS
Cancer Res; 1986 May; 46(5):2340-3. PubMed ID: 2938728
[TBL] [Abstract][Full Text] [Related]
5. Amino acid-conferred protection against melphalan--characterization of melphalan transport and correlation of uptake with cytotoxicity in cultured L1210 murine leukemia cells.
Vistica DT; Toal JN; Rabinovitz M
Biochem Pharmacol; 1978; 27(24):2865-70. PubMed ID: 736979
[No Abstract] [Full Text] [Related]
6. Role of cytoprotective mechanisms in the photochemical purging of autologous bone marrow grafts.
Yamazaki T; Sato Y; Sieber F
Exp Hematol; 1997 Jul; 25(7):629-37. PubMed ID: 9216739
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
8. Effects of amino acids on the transport and cytotoxicity of melphalan by human bone marrow cells and human tumor cells.
Dufour M; Panasci LC; St Germain J; Boulet L
Cancer Chemother Pharmacol; 1985; 15(2):125-31. PubMed ID: 4017161
[TBL] [Abstract][Full Text] [Related]
9. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update.
Peters RH; Brandon CS; Avila LA; Gale GR; Stuart RK
Prog Clin Biol Res; 1990; 333():57-68. PubMed ID: 2309001
[TBL] [Abstract][Full Text] [Related]
10. Ethanol mustard cytotoxicity in vitro toward murine leukemia and bone marrow progenitor cells.
Naujokaitis SA; Fisher JM; Rabinovitz M
Res Commun Chem Pathol Pharmacol; 1981 Aug; 33(2):305-18. PubMed ID: 7302378
[TBL] [Abstract][Full Text] [Related]
11. Biologic effects of prolonged melphalan treatment of murine long-term bone marrow cultures and interleukin 3-dependent hematopoietic progenitor cell lines.
Greenberger JS; Palaszynski EW; Pierce JH; Sakakeeny MA; Ruscetti SK; Ihle JN; Daugherty C
J Natl Cancer Inst; 1985 Jan; 74(1):247-62. PubMed ID: 3918212
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity as an indicator for transport mechanism: evidence that melphalan is transported by two leucine-preferring carrier systems in the L1210 murine leukemia cell.
Vistica DT
Biochim Biophys Acta; 1979 Jan; 550(2):309-17. PubMed ID: 569503
[TBL] [Abstract][Full Text] [Related]
13. 6-[Bis(2-chloroethyl)amino]-6-deoxygalactopyranose hydrochloride (C6-galactose mustard), a new alkylating agent with reduced bone marrow toxicity.
Schein PS; Green D; Dean SW; McPherson E
Cancer Res; 1987 Feb; 47(3):696-9. PubMed ID: 3802075
[TBL] [Abstract][Full Text] [Related]
14. Differential cytotoxicity of cytosine arabinoside toward murine leukemia L1210 cells and murine bone marrow progenitor cells inhibited in nucleoside transport by cimicifugoside.
Hemmi H
Res Commun Chem Pathol Pharmacol; 1981 Jun; 32(3):565-8. PubMed ID: 6791252
[TBL] [Abstract][Full Text] [Related]
15. Comparative heat sensitivity of murine and human hemopoietic progenitors and clonogenic leukemia cells.
Gidáli J; Fehér I; Kovács P
Stem Cells; 1994 Sep; 12(5):533-8. PubMed ID: 7804126
[TBL] [Abstract][Full Text] [Related]
16. Cain's quinolinium (NSC 176319): protection of murine L1210 leukemia cells and bone marrow progenitor cells against mechlorethamine cytotoxicity and its application to combination chemotherapy.
Naujokaitis SA
Res Commun Chem Pathol Pharmacol; 1981 Oct; 34(1):97-104. PubMed ID: 7313308
[TBL] [Abstract][Full Text] [Related]
17. The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion.
Pinedo HM; Zaharko DS; Bull J; Chabner BA
Cancer Res; 1977 Feb; 37(2):445-50. PubMed ID: 832268
[TBL] [Abstract][Full Text] [Related]
18. In vitro chemoseparation of leukemic cells from murine bone marrow using VP16-213: importance of stem cell assays.
Stiff PJ; Koester AR
Exp Hematol; 1987 Mar; 15(3):263-8. PubMed ID: 3545881
[TBL] [Abstract][Full Text] [Related]
19. Effect of methotrexate on murine bone marrow cells in vitro: evidence of a reversible antiproliferative action.
Strømhaug A; Warren DJ; Slørdal L
Exp Hematol; 1995 May; 23(5):439-43. PubMed ID: 7720815
[TBL] [Abstract][Full Text] [Related]
20. The selective antiproliferative effects of alpha-tocopheryl hemisuccinate and cholesteryl hemisuccinate on murine leukemia cells result from the action of the intact compounds.
Fariss MW; Fortuna MB; Everett CK; Smith JD; Trent DF; Djuric Z
Cancer Res; 1994 Jul; 54(13):3346-51. PubMed ID: 8012947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
